Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 196

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 196
---
ulating medicines for unmet market needs. Prof. Tam’s research projects over the past twenty years has crossed subjects, disciplines and methodologies, yet the main research interests remain focused on the different pathophysiological aspects of the endocannabinoid system. Having a clinical background with basic science training, he has always been interested in how science can directly improve people’s everyday lives. Thus, he has strived unceasingly to integrate his clinical curiosity and experimental knowledge, in order to deepen the understanding of clinically relevant research questions. Fatima Cody Stanford, MD, MPH, MPA,is currently associated with Massachusetts General Hospital and is an Associate Professor of Medicine and Pediatrics at Harvard Medical School, where she serves as an educator, researcher, and policy maker. Her extensive academic background includes a Bachelor of Science and Master of Public Health from Emory University, a MD from the Medical College of Georgia School of Medicine, a Masters of Public Administration from the Harvard Kennedy School of Government and a MBA from the Quantic School of Business and Technology. Dr. Stanford completed her Obesity Medicine & Nutrition Fellowship at Massachusetts General Hospital and Harvard Medical School, further enhancing her expertise in the field. With a career dedicated to bridging the gaps between medicine, public health, and policy, Dr. Stanford has become a sought-after expert in obesity medicine, both nationally and internationally. Prof. Henry R. Kranzler, MD, PhD, is the Benjamin Rush Professor of Psychiatry, and Director of the Center for Studies of Addiction, at the University of Pennsylvania’s Perelman School of Medicine. His research focuses on the genetics and pharmacological treatment of substance dependence, with emphasis on precision addiction medicine. His research has been continuously supported since 1987 by grants from the National Institutes of Health. Professor Kranzler has authored or co-authored more than 600 journal articles, book chapters, and books, is a member of the editorial board of three peer-review journals as well as the editor of Alcohol: Clinical and Experimental Research. His work currently focuses on the molecular genetics of substance dependence and the personalized treatment of alcohol, opioid, and nicotine use disorders using a pharmacogenetic approach. 118 Arrangements for Election of Directors and Members of Management There are no arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our executive management or our directors were selected. See “Item 7.B. Related Party Transactions” for additional information. Compensation The following table presents in the aggregate all compensation we paid to all of our directors and senior management as a